Femasys Inc
FEMY- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001339005
In the last 90 days, Femasys Inc insiders filed 5 open-market purchases and 0 sales; 19 institutions reported holding it in 13F filings for Q2 2026, worth $8.65M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Femasys Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 5 filings
- 5 insiders, $134.0K in total
- Open-market sells
- 0 filings
- Insiders trading
- 5
- Net value
- +$134.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Femasys Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Eichenbaum Kenneth D. | Director | – | Aug 11, 2026 | 3 |
| Uzialko Edward R | Director | – | Aug 11, 2026 | 1 |
| Milnes Alistair | Director | – | Aug 11, 2026 | 1 |
| Larsen Charles | Director | 56 | Aug 11, 2026 | 3 |
| Mifek Jeffrey Gerald | Chief Clinical-Medical Affairs | 3,125 | Aug 11, 2026 | 2 |
| Sipos Jeremy Alexander | Chief Technology Officer | 3,125 | Aug 11, 2026 | 2 |
| Canning John Charles | Chief Operating Officer | 4,375 | Aug 11, 2026 | 2 |
| Elefant Dov | Chief Financial Officer | 15,625 | Aug 11, 2026 | 4 |
| Lee-Sepsick Kathy | Chief Executive Officer | 15,625 | Aug 11, 2026 | 4 |
| PharmaCyte Biotech, Inc. | 10% Owner | – | Mar 18, 2026 | 1 |
| Silverman Joshua | Director | – | Mar 18, 2026 | 1 |
| Nicholas Kelley Stinson | Chief Commercial Officer | – | Jul 1, 2025 | 0 |
| Currie Daniel Scott | Chief Operating Officer | 86,275 | Jun 4, 2025 | 0 |
| Thomas Christine E | Chief Reg & Clinical Officer | – | Jan 30, 2025 | 0 |
| Spector Richard D. | Chief Commercial Officer | – | Feb 13, 2024 | 0 |
| Perrow Wendy | Director | – | Jun 23, 2023 | 0 |
| Morrissey Anne | Director | – | Jun 23, 2023 | 0 |
| Kendall Keith J | Director | – | Jun 16, 2023 | 0 |
| Dyett John | Director | 290,344Indirect | Jun 10, 2022 | 0 |
| Adams John Q JR | Director | – | Jun 10, 2022 | 0 |
| Witte William Benson | Director | 12,191 | Dec 17, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 (view filing)8:54 PM ET | Aug 7 | 4 days | Mifek Jeffrey GeraldChief Clinical-Medical Affairs | PPurchase | +3.13K | $3.20 | +$10.0K | New position3.13K after | |
| Aug 11, 2026 (view filing)8:44 PM ET | Aug 7 | 4 days | Sipos Jeremy AlexanderChief Technology Officer | PPurchase | +3.13K | $3.20 | +$10.0K | New position3.13K after | |
| Aug 11, 2026 (view filing)8:40 PM ET | Aug 7 | 4 days | Canning John CharlesChief Operating Officer | PPurchase | +4.38K | $3.20 | +$14.0K | New position4.38K after | |
| Aug 11, 2026 (view filing)8:37 PM ET | Aug 7 | 4 days | Elefant DovChief Financial Officer | PPurchase | +15.6K | $3.20 | +$50.0K | New position15.6K after | |
| Aug 11, 2026 (view filing)8:30 PM ET | Aug 7 | 4 days | Lee-Sepsick KathyChief Executive Officer | PPurchase | +15.6K | $3.20 | +$50.0K | New position15.6K after |